ANTX שווי כולל של נכסי החברה AN2 Bio

The AN2 Therapeutics, Inc. (ANTX) R&D center focuses on developing advanced treatments against rare mycobacteria, including epitaraborol trials. This chart of total asset price dynamics, with a value of 78.77, highlights the business's dependence on grants and the test results of orphan drugs. The company's growth relies on partnerships with global scientific organizations to jointly bring new antibiotics to market.

The metric is calculated inversely via ROA, which allows for the tracking of daily changes in the resource base and the sensitivity of capital to operational efficiency. The combination of assets and liabilities reflects the financial potential of AN2 Therapeutics, Inc. (ANTX) in developing oral treatments for pulmonary infections; therefore, the company's asset dynamics serve as an indicator of the business's ability to scale innovations within a narrow niche.